Top

Published in:

Open Access 01-12-2023 | Migraine | Research

FGF-21 and GDF-15 are increased in migraine and associated with the severity of migraine-related disability

Authors: Jiahui He, Mengting Zhou, Fanglin Zhao, Hongrong Cheng, Hao Huang, Xiaopei Xu, Jian Han, Wenwu Hong, Faming Wang, Yujin Xiao, Jinjin Xia, Kaiming Liu

Published in: The Journal of Headache and Pain | Issue 1/2023

Abstract

Background

Migraine is a prevalent disorder with significant socioeconomic impact. The impairment of metabolic homeostasis in migraine warrants further investigation. Changes in serum levels of Fibroblast-growth-factor 21 (FGF-21) and Growth-differentiation-factor 15 (GDF-15) are characteristic of some metabolic and mitochondrial diseases. This study aimed to assess whether the presence of migraine affects serum levels of FGF-21 and GDF-15, and taking metabolic disorders into account as potential confounding factors.

Methods

We collected serum samples from 221 migraine patients (153 episodic migraineurs and 68 chronic migraineurs) and 124 healthy controls. The serum concentrations of FGF-21 and GDF-15 were measured using an enzyme-linked immunosorbent assay (ELISA) based approach. Clinical variables, including monthly headache days, peak headache pain intensity, the 6-item Headache Impact Test (HIT-6), and the Migraine Disability Assessment (MIDAS), were also addressed. The associations between the clinical variables of migraine patients and serum levels of FGF-21 and GDF-15 were studied.

Results

In the multiple regression that corrected for age, we found that the serum levels of FGF-21 and GDF-15 were significantly higher in migraine sufferers than in healthy controls. A significant elevation in serum concentration of FGF-21, but not GDF-15, was observed in patients with chronic migraine (CM) compared to those with episodic migraine (EM). Regarding migraine-related disability, higher scores on the HIT-6 and MIDAS were associated with higher levels of FGF-21 and GDF-15. For the receiver operating characteristic (ROC) analysis, the diagnosis of migraine using GDF-15 showed that the area under the ROC curve (AUC) was 0.801 and the AUC of chronic migraine was 0.880.

Conclusion

Serum GDF-15 and FGF-21 levels are increased in patients with migraine and associated with the severity of migraine-related disability.

Feigin V, Vos T, Nichols E, Owolabi M, Carroll W, Dichgans M et al (2020) The global burden of neurological disorders: translating evidence into policy. Lancet Neurol 19:255–265. https://doi.org/10.1016/s1474-4422(19)30411-9CrossRefPubMed

Gross E, Lisicki M, Fischer D, Sándor P, Schoenen J (2019) The metabolic face of migraine - from pathophysiology to treatment. Nat Rev Neurol 15:627–643. https://doi.org/10.1038/s41582-019-0255-4CrossRefPubMed

Powers S, Radak Z, Ji L (2016) Exercise-induced oxidative stress: past, present and future. J Physiol 594:5081–5092. https://doi.org/10.1113/jp270646CrossRefPubMedPubMedCentral

Pingitore A, Lima G, Mastorci F, Quinones A, Iervasi G, Vassalle C (2015) Exercise and oxidative stress: potential effects of antioxidant dietary strategies in sports. Nutrition 31:916–922. https://doi.org/10.1016/j.nut.2015.02.005CrossRefPubMed

Schiavone S, Jaquet V, Trabace L, Krause K (2013) Severe life stress and oxidative stress in the brain: from animal models to human pathology. Antioxid Redox Signal 18:1475–1490. https://doi.org/10.1089/ars.2012.4720CrossRefPubMedPubMedCentral

Schoonman G, Evers D, Terwindt G, van Dijk J, Ferrari M (2006) The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia 26:1209–1213. https://doi.org/10.1111/j.1468-2982.2006.01195.xCrossRefPubMed

Arngrim N, Schytz H, Britze J, Amin F, Vestergaard M, Hougaard A et al (2016) Migraine induced by hypoxia: an MRI spectroscopy and angiography study. Brain 139:723–737. https://doi.org/10.1093/brain/awv359CrossRefPubMed

Broessner G, Rohregger J, Wille M, Lackner P, Ndayisaba J, Burtscher M (2016) Hypoxia triggers high-altitude headache with migraine features: A prospective trial. Cephalalgia 36:765–771. https://doi.org/10.1177/0333102415610876CrossRefPubMed

Trivedi M, Holger D, Bui A, Craddock T, Tartar J (2017) Short-term sleep deprivation leads to decreased systemic redox metabolites and altered epigenetic status. PloS one. 12:e0181978. https://doi.org/10.1371/journal.pone.0181978CrossRefPubMedPubMedCentral

10.

Angelucci F, Silva V, Dal Pizzol C, Spir L, Praes C, Maibach H (2014) Physiological effect of olfactory stimuli inhalation in humans: an overview. Int J Cosmetic Sci 36:117–123. https://doi.org/10.1111/ics.12096CrossRef

11.

Franken C, Lambrechts N, Govarts E, Koppen G, Den Hond E, Ooms D et al (2017) Phthalate-induced oxidative stress and association with asthma-related airway inflammation in adolescents. Int J Hyg Envir Heal 220:468–477. https://doi.org/10.1016/j.ijheh.2017.01.006CrossRef

12.

Kwiatkowska K, Bacalini M, Sala C, Kaziyama H, de Andrade D, Terlizzi R et al (2020) Analysis of Epigenetic Age Predictors in Pain-Related Conditions. Front 8:172. https://doi.org/10.3389/fpubh.2020.00172CrossRef

13.

Hahad O, Prochaska J, Daiber A, Muenzel T (2019) Environmental Noise-Induced Effects on Stress Hormones, Oxidative Stress, and Vascular Dysfunction: Key Factors in the Relationship between Cerebrocardiovascular and Psychological Disorders. Oxid Med Cell Longev 2019:4623109. https://doi.org/10.1155/2019/4623109CrossRefPubMedPubMedCentral

14.

Reyngoudt H, Achten E, Paemeleire K (2012) Magnetic resonance spectroscopy in migraine: what have we learned so far? Cephalalgia 32:845–859. https://doi.org/10.1177/0333102412452048CrossRefPubMed

15.

Sándor P, Dydak U, Schoenen J, Kollias S, Hess K, Boesiger P et al (2005) MR-spectroscopic imaging during visual stimulation in subgroups of migraine with aura. Cephalalgia 25:507–518. https://doi.org/10.1111/j.1468-2982.2005.00900.xCrossRefPubMed

16.

Yorns W, Hardison H (2013) Mitochondrial dysfunction in migraine. Seminars in pediatric neurology 20:188–193. https://doi.org/10.1016/j.spen.2013.09.002CrossRefPubMed

17.

Okada H, Araga S, Takeshima T, Nakashima K (1998) Plasma lactic acid and pyruvic acid levels in migraine and tension-type headache. Headache 38:39–42. https://doi.org/10.1046/j.1526-4610.1998.3801039.xCrossRefPubMed

18.

Eikermann-Haerter K, Dileköz E, Kudo C, Savitz S, Waeber C, Baum M et al (2009) Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. J Clin Investig 119:99–109. https://doi.org/10.1172/jci36059CrossRefPubMed

19.

Littlewood J, Glover V, Sandler M, Peatfield R, Petty R, Clifford Rose F (1984) Low platelet monoamine oxidase activity in headache: no correlation with phenolsulphotransferase, succinate dehydrogenase, platelet preparation method or smoking. J Neurol Neurosurg Psychiatry 47:338–343. https://doi.org/10.1136/jnnp.47.4.338CrossRefPubMedPubMedCentral

20.

Sangiorgi S, Mochi M, Riva R, Cortelli P, Monari L, Pierangeli G et al (1994) Abnormal platelet mitochondrial function in patients affected by migraine with and without aura. Cephalalgia 14:21–23. https://doi.org/10.1046/j.1468-2982.1994.1401021.xCrossRefPubMed

21.

Sparaco M, Feleppa M, Lipton R, Rapoport A, Bigal M (2006) Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia 26:361–372. https://doi.org/10.1111/j.1468-2982.2005.01059.xCrossRefPubMed

22.

Woldeamanuel Y, Rapoport A, Cowan R (2015) The place of corticosteroids in migraine attack management: A 65-year systematic review with pooled analysis and critical appraisal. Cephalalgia 35:996–1024. https://doi.org/10.1177/0333102414566200CrossRefPubMed

23.

Derry C, Derry S, and Moore R (2014) Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database Syst. Rev. 2014:CD009281. https://doi.org/10.1002/14651858.CD009281.pub3.

24.

Kim K, Lee M (2021) GDF15 as a central mediator for integrated stress response and a promising therapeutic molecule for metabolic disorders and NASH. Biochim. Biophys. Acta. Gen. Subj. 1865:129834. https://doi.org/10.1016/j.bbagen.2020.129834CrossRefPubMed

25.

Fujita Y, Taniguchi Y, Shinkai S, Tanaka M, and Ito M (2016) Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders. Geriatr. Gerontol. Int.:17–29. https://doi.org/10.1111/ggi.12724.

26.

Strelau J, Sullivan A, Böttner M, Lingor P, Falkenstein E, Suter-Crazzolara C et al (2000) Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo. J Neurosci 20:8597–8603. https://doi.org/10.1523/jneurosci.20-23-08597.2000CrossRefPubMedPubMedCentral

27.

Subramaniam S, Strelau J, Unsicker K (2003) Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways. J Biol Chem 278:8904–8912. https://doi.org/10.1074/jbc.M210037200CrossRefPubMed

28.

Li P, Lv H, Zhang B, Duan R, Zhang X, Lin P et al (2022) Growth Differentiation Factor 15 Protects SH-SY5Y Cells From Rotenone-Induced Toxicity by Suppressing Mitochondrial Apoptosis. Front. in Aging Neurosci 14:869558. https://doi.org/10.3389/fnagi.2022.869558CrossRef

29.

Montero R, Yubero D, Villarroya J, Henares D, Jou C, Rodríguez M et al (2016) GDF-15 Is Elevated in Children with Mitochondrial Diseases and Is Induced by Mitochondrial Dysfunction. PloS one 11:e0148709. https://doi.org/10.1371/journal.pone.0148709CrossRefPubMedPubMedCentral

30.

Cardoso A, Fernandes A, Aguilar-Pimentel J, de Angelis M, Guedes J, Brito M et al (2018) Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases. Ageing Res Rev 47:214–277. https://doi.org/10.1016/j.arr.2018.07.004CrossRefPubMed

31.

Davis R, Liang C, Sue C (2016) A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases. Neurology 86:2010–2015. https://doi.org/10.1212/wnl.0000000000002705CrossRefPubMedPubMedCentral

32.

Keipert S, Ost M (2021) Stress-induced FGF21 and GDF15 in obesity and obesity resistance. Trends Endocrin Met 32:904–915. https://doi.org/10.1016/j.tem.2021.08.008CrossRef

33.

Conte M, Martucci M, Chiariello A, Franceschi C, Salvioli S (2020) Mitochondria, immunosenescence and inflammaging: a role for mitokines? Semin Immunopathol 42:607–617. https://doi.org/10.1007/s00281-020-00813-0CrossRefPubMedPubMedCentral

34.

Grech O, Mollan S, Wakerley B, Fulton D, Lavery G, and Sinclair A (2021) The Role of Metabolism in Migraine Pathophysiology and Susceptibility. Life-Basel. 11. http://doi.org/https://doi.org/10.3390/life11050415.

35.

van Tilburg M, Parisien M, Boles R, Drury G, Smith-Voudouris J, Verma V et al (2020) A genetic polymorphism that is associated with mitochondrial energy metabolism increases risk of fibromyalgia. Pain 161:2860–2871. https://doi.org/10.1097/j.pain.0000000000001996CrossRefPubMedPubMedCentral

36.

Boles R, Zaki E, Lavenbarg T, Hejazi R, Foran P, Freeborn J et al (2009) Are pediatric and adult-onset cyclic vomiting syndrome (CVS) biologically different conditions? Relationship of adult-onset CVS with the migraine and pediatric CVS-associated common mtDNA polymorphisms 16519T and 3010A. Neurogastroenterol Motil 21:936-e972. https://doi.org/10.1111/j.1365-2982.2009.01305.xCrossRefPubMed

37.

Zaki E, Freilinger T, Klopstock T, Baldwin E, Heisner K, Adams K et al (2009) Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome. Cephalalgia 29:719–728. https://doi.org/10.1111/j.1468-2982.2008.01793.xCrossRefPubMed

38.

Verhamme F, Freeman C, Brusselle G, Bracke K, Curtis J (2019) GDF-15 in Pulmonary and Critical Care Medicine. Am J Respir Cell Mol Biol 60:621–628. https://doi.org/10.1165/rcmb.2018-0379TRCrossRefPubMedPubMedCentral

39.

Wischhusen J, Melero I, Fridman W (2020) Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol 11:951. https://doi.org/10.3389/fimmu.2020.00951CrossRefPubMedPubMedCentral

40.

May A, Schulte L (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12:455–464. https://doi.org/10.1038/nrneurol.2016.93CrossRefPubMed

41.

Scher A, Stewart W, Ricci J, Lipton R (2003) Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106:81–89. https://doi.org/10.1016/s0304-3959(03)00293-8CrossRefPubMed

42.

Buse D, Manack A, Fanning K, Serrano D, Reed M, Turkel C et al (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 52:1456–1470. https://doi.org/10.1111/j.1526-4610.2012.02223.xCrossRefPubMed

43.

Buse D, Manack A, Serrano D, Turkel C, Lipton R (2010) Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 81:428–432. https://doi.org/10.1136/jnnp.2009.192492CrossRefPubMed

44.

Amorim J, Coppotelli G, Rolo A, Palmeira C, Ross J, Sinclair D (2022) Mitochondrial and metabolic dysfunction in ageing and age-related diseases. Nat Rev Endocrinol 18:243–258. https://doi.org/10.1038/s41574-021-00626-7CrossRefPubMedPubMedCentral

45.

Kato E, Morrow D, Guo J, Berg D, Blazing M, Bohula E et al (2023) Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. Eur Heart J 44:293–300. https://doi.org/10.1093/eurheartj/ehac577CrossRefPubMed

46.

Amstad A, Coray M, Frick C, Barro C, Oechtering J, Amann M et al (2020) Growth differentiation factor 15 is increased in stable MS. Neurol Neuroimmunol Neuroinflamm 7:e675. https://doi.org/10.1212/nxi.0000000000000675CrossRefPubMedPubMedCentral

47.

Ducros A, de Gaalon S, Roos C, Donnet A, Giraud P, Guégan-Massardier E et al (2021) Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: Pharmacological treatment. Revue neurologique 177:734–752. https://doi.org/10.1016/j.neurol.2021.07.006CrossRefPubMed

Title: FGF-21 and GDF-15 are increased in migraine and associated with the severity of migraine-related disability
Authors: Jiahui He
Mengting Zhou
Fanglin Zhao
Hongrong Cheng
Hao Huang
Xiaopei Xu
Jian Han
Wenwu Hong
Faming Wang
Yujin Xiao
Jinjin Xia
Kaiming Liu
Publication date: 01-12-2023
Publisher: Springer Milan
Keywords: Migraine
Medication Overuse Headache
Headache
Published in: The Journal of Headache and Pain / Issue 1/2023
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-023-01563-8

2024 ASCO Annual Meeting

Springer Medicine

FGF-21 and GDF-15 are increased in migraine and associated with the severity of migraine-related disability

Abstract

Background

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Verification of a clinical decision support system for the diagnosis of headache disorders based on patient–computer interactions: a multi-center study

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study

Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients

Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis

Sphenopalatine ganglion volumetry in episodic cluster headache: from symptom laterality to cranial autonomic symptoms

Shared and independent roles of CGRP and PACAP in migraine pathophysiology